Schicho Rudolf, Storr Martin
Medical University of Graz, Austria.
Can J Gastroenterol. 2011 Jul;25(7):377-83. doi: 10.1155/2011/953975.
Many beneficial effects of herbal and synthetic cannabinoids on gut motility and inflammation have been demonstrated, suggesting a vast potential for these compounds in the treatment of gastrointestinal disorders. These effects are based on the so-called 'endocannabinoid system' (ECS), a cooperating network of molecules that regulate the metabolism of the body's own and of exogenously administered cannabinoids. The ECS in the gastrointestinal tract quickly responds to homeostatic disturbances by de novo synthesis of its components to maintain homeostasis, thereby offering many potential targets for pharmacological intervention. Of major therapeutic interest are nonpsychoactive cannabinoids or compounds that do not directly target cannabinoid receptors but still possess cannabinoid-like properties. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids are becoming increasingly promising alternative therapeutic tools to manipulate the ECS.
草药和合成大麻素对肠道蠕动和炎症具有许多有益作用，这表明这些化合物在治疗胃肠道疾病方面具有巨大潜力。这些作用基于所谓的“内源性大麻素系统”（ECS），这是一个由分子组成的协作网络，可调节体内自身和外源性大麻素的代谢。胃肠道中的ECS通过从头合成其成分来快速响应体内稳态紊乱，以维持体内平衡，从而提供了许多药理学干预的潜在靶点。具有重大治疗意义的是非精神活性大麻素或不直接靶向大麻素受体但仍具有类大麻素特性的化合物。抑制内源性大麻素降解并提高内源性大麻素水平的药物正日益成为操纵ECS的有前景的替代治疗工具。
